跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

V4890

Sigma-Aldrich

Vindesine sulfate salt hydrate

≥95% (HPLC)

别名:

3-(Aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine sulfate salt hydrate, Desacetylvinblastine amide sulfate salt hydrate

登录查看公司和协议定价

选择尺寸

5 MG
$126.00
25 MG
$505.00

$126.00

请联系客服了解存货情况
获取大包装报价
所有图片(1)

选择尺寸

变更视图
5 MG
$126.00
25 MG
$505.00

About This Item

经验公式（希尔记法）:
C43H55N5O7 · H2SO4 · xH2O
CAS号:
59917-39-4
分子量:
852.00 (anhydrous basis)
UNSPSC代码:
12352200
PubChem化学物质编号:
329829055
NACRES:
NA.77

$126.00

请联系客服了解存货情况
获取大包装报价

方案

≥95% (HPLC)

表单

powder

颜色

off-white to light yellow

溶解性

deionized water: ≥50 mg/mL

创始人

Eli Lilly

储存温度

−20°C

SMILES字符串

O.OS(O)(=O)=O.CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](O)[C@]8(CC)C=CC[N@H]9CC[C@]67[C@H]89)C(N)=O)C1

InChI

1S/C43H55N5O7.H2O4S.H2O/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50;1-5(2,3)4;/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50);(H2,1,2,3,4);1H2/t25-,34+,35-,36-,39+,40-,41-,42+,43+;;/m1../s1

InChI key

TUDLKTILIBRXNU-RIHOAIHNSA-N

生化/生理作用

Microtubule inhibitor
Microtubule inhibitor. Vindesine binds to and stabilizes tubulin, thereby preventing tubulin polymerization, preventing mitosis, and arresting cells in metaphase.

特点和优势

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000380562
0000380562
0000078262
0000078263
056M4730V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Katrin Patrij et al.
German medical science : GMS e-journal, 9, Doc11-Doc11 (2011-06-24)
We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin's lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003-12/2007 were included into this analysis.
Haoyuan Zhang et al.
Internal medicine (Tokyo, Japan), 51(12), 1537-1542 (2012-06-26)
We report two cases of membranoproliferative glomerulonephritis, involved in Castleman's disease of hyaline vascular variant and mixed variant, respectively. The diagnoses were confirmed by cervical lymph node and renal biopsy. Both cases were sensitive to chemotherapy with cyclophosphamide, vindesine and
René-Olivier Casasnovas et al.
Blood, 118(1), 37-43 (2011-04-27)
The prognostic value of interim positron emission tomography (PET) interpreted according to visual criteria is a matter of debate in diffuse large B-cell lymphoma (DLBCL). Maximal standardized uptake value reduction (ΔSUVmax) may better predict outcome. To compare the prognostic value
N Ketterer et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 24(4), 1032-1037 (2012-12-14)
The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the results
Thomas M Habermann
Hematology (Amsterdam, Netherlands), 17 Suppl 1, S93-S97 (2012-04-25)
Diffuse large B-cell lymphoma is the most common adult non-Hodgkin lymphoma and is potentially curable. Immunochemotherapy, R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone) is the standard of care. This regimen has been incorporated in other approaches and reevaluated in different
查看所有相关文献

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门